- Home
- RWAY vs RLMD Comparison
RWAY vs RLMD Comparison
Compare RWAY & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RWAY | RLMD |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.2M | 319.7M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | RWAY | RLMD |
|---|---|---|
| Price | $7.18 | $6.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $11.08 | $10.25 |
| AVG Volume (30 Days) | 417.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 19.55% | N/A |
| EPS Growth | N/A | ★ 19.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.96 | N/A |
| P/E Ratio | $5.70 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $7.16 | $0.24 |
| 52 Week High | $11.41 | $7.41 |
Technical Indicators
Market Signals| Indicator | RWAY | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 21.41 | 63.36 |
| Support Level | N/A | $3.74 |
| Resistance Level | $10.07 | N/A |
| Average True Range (ATR) | 0.24 | 0.47 |
| MACD | -0.06 | 0.21 |
| Stochastic Oscillator | 1.78 | 63.08 |
Price Performance
Historical ComparisonAbout RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.